Results 161 to 170 of about 231,717 (193)

Transthyretin amyloid cardiomyopathy

The American Journal of the Medical Sciences, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure and arrhythmia. This differential diagnosis should particularly be considered in older patients with left ventricular hypertrophy (LVH) who are also suffering from heart failure with preserved ejection fraction (HFpEF) or aortic valve stenosis.
Giuseppe, Famularo, Guido, Ventroni
openaire   +4 more sources

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy [PDF]

New England Journal of Medicine
In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than ...
Mathew S Maurer, James Hoffman, Uma Sinha   +2 more
exaly   +4 more sources

Transthyretin Amyloid Cardiomyopathy

Journal of the American College of Cardiology, 2019
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin. Characteristic patterns of echocardiography and cardiac magnetic resonance can strongly suggest the disease but are not diagnostic.
Mathew S Maurer, Jeffery W. Kelly
exaly   +3 more sources

Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy

American Journal of Therapeutics, 2021
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide drugs (revusiran, patisiran, and inotersen).
Courtney M, Campbell, Cyril Ayuk Mbeng Takem, Baiyee, Salem, Almaani, Naresh, Bumma, Nidhi, Sharma, Samantha, LoRusso, Elyse, Redder, Jordan, Bittengle, Katherine, Pfund, Miriam, Friemer, Matthew, Tong, Rami, Kahwash, Yvonne, Efebera, Samir, Parikh, Ajay, Vallakati   +14 more
openaire   +2 more sources

Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy [PDF]

European Journal of Heart Failure, 2021
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a life‐threatening condition with a heterogeneous clinical presentation. The recent availability of treatment for ATTR‐CM has stimulated increased awareness of the disease and patient identification.
Laura Obici, Pablo Garcia-Pavia, Jose Nativi-Nicolau   +2 more
exaly   +8 more sources

Tafamidis for Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine, 2019
Abstract not ...
Maurer, Mathew S, Sultan, Marla B, Rapezzi, Claudio   +2 more
openaire   +4 more sources

Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy

American Journal of Cardiovascular Drugs, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by the aggregation and deposition of amyloidogenic misfolded transthyretin (TTR) in the myocardium. The gradual accumulation of insoluble TTR amyloid fibrils can result in restrictive cardiomyopathy and heart failure. Tafamidis (Vyndaqel®; Vyndamax®),
openaire   +2 more sources

Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy

Annals of Pharmacotherapy, 2019
Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials. gov search was conducted using the keywords tafamidis, Fx-1006A, Vyndaqel, and Vyndamax.
Jonathan Park, Ugochukwu Egolum, Shanea Parker, Ebony Andrews, David Ombengi, Hua Ling   +5 more
openaire   +2 more sources

Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy.

Heart Failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that results from myocardial deposition of misfolded transthyretin (TTR) protein. The biology of amyloid formation has been elucidated resulting in several effective therapeutic strategies.
Mathew S Maurer, Ahmad Masri, Frederick L. Ruberg   +2 more
exaly   +3 more sources

Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation

Journal of Cardiovascular Translational Research, 2019
Tyr78Phe is a rare pathogenic transthyretin (TTR) mutation. Few previous reports described a late-onset hereditary transthyretin-related amyloidosis (ATTR-m) form with a variable phenotype, mainly dominated by neurological manifestations. We describe the case of a 69-year-old male with massive but asymptomatic cardiac infiltration and only subclinical ...
Tini, Giacomo, Vianello, Pier Filippo, Gemelli, Chiara, Grandis, Marina, Canepa, Marco   +4 more
openaire   +3 more sources